> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Astria Gets Fast Track for Angioedema Drug
- URL: https://www.fdaweb.com/astria-gets-fast-track-for-angioedema-drug/
- Published: 2023-07-20T12:00:00.000Z
- Updated: 2026-09-14T18:45:21.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154924

FDA has granted Astria Therapeutics fast track status for STAR-0215 for treating hereditary angioedema (HAE), a rare genetic disorder that causes severe unpredictable swelling attacks throughout the body. The therapy is currently being evaluated in the ALPHA-STAR clinical trial in people with HAE, and “initial proof-of-concept results expected in mid-2024,” according to the company.

Astria describes STAR-0215 as a monoclonal antibody inhibitor of plasma kallikrein. It is designed to be dosed once every three or six months, it says.